Physician profile
Mark Silva
NPI 1508158718
$41,013.25
in general payments reported to CMS, 2019-2025
51 companies · $7,973 in 2025
The $7,973 reported for 2025 was more than what 93% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $843 · 2021: $3,180 · 2022: $22K · 2023: $4,860 · 2024: $1,587 · 2025: $7,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,671 · Food and Beverage: $4,496 · Honoraria: $1,200 · Travel and Lodging: $53.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,670.50 |
| Food and Beverage | $4,496.23 |
| Honoraria | $1,200.00 |
| Travel and Lodging | $53.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $31,672.60 | 2019-2025 | General - Kidney Stone Disease, Advantage System, Lithovue |
| Ferring Pharmaceuticals INC. | $3,384.76 | 2024-2025 | Adstiladrin |
| Ambu A/S | $1,200.00 | 2023 | |
| Janssen Biotech, INC. | $587.25 | 2024-2025 | Erleada, Rybrevant, Carvykti |
| Astellas Pharma US INC | $442.12 | 2022-2025 | Xtandi, Myrbetriq |
| Immunitybio, INC. | $422.66 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $303.81 | 2023-2025 | Gemtesa |
| Convatec INC. | $263.53 | 2022-2025 | |
| Urogen Pharma, INC. | $259.12 | 2021-2024 | Jelmyto |
| Dendreon Pharmaceuticals LLC | $205.45 | 2022-2025 | Provenge |
| Dentsply Ih Ab | $200.00 | 2023-2024 | Lofric, Lofric |
| Progenics Pharmaceuticals, INC. | $156.15 | 2023 | Pylarify |
| Alnylam Pharmaceuticals INC. | $138.50 | 2020-2022 | |
| 180 Medical, INC. | $136.85 | 2023-2024 | Gentlecath, Gentlecath Glide |
| Antares Pharma, INC. | $136.59 | 2022-2025 | Xyosted, Tlando |
Show all 50 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.